What Next for Sarepta Therapeutics, Inc. (SRPT) Stock After Touching 52-Week High?

May 17, 2018 - By Margaret Downey

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Logo

Investors sentiment decreased to 1.22 in 2017 Q4. Its down 1.66, from 2.88 in 2017Q3. It worsened, as 27 investors sold Sarepta Therapeutics, Inc. shares while 67 reduced holdings. 45 funds opened positions while 70 raised stakes. 52.88 million shares or 2.28% more from 51.70 million shares in 2017Q3 were reported.
384,997 are held by Sphera Funds Mgmt Ltd. Oppenheimer And Inc has invested 0.05% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Bessemer Grp holds 0% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for 1,000 shares. Macquarie Grp Inc holds 23,000 shares. Sei Invests has invested 0.01% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Elk Creek Prtn Limited Liability, a Colorado-based fund reported 703,424 shares. Creative Planning has 0.02% invested in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). 29,575 are owned by Tocqueville Asset Management Limited Partnership. Osterweis Capital Management holds 0.31% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for 77,440 shares. 5,500 are held by Lucas Capital Management. Tourbillon Prtn Lp has invested 1.91% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Us Natl Bank De reported 4,224 shares. Bb&T Secs Ltd invested in 5,709 shares or 0% of the stock. 303,006 are owned by Pinnacle Assoc Limited. Arrowstreet Cap Ltd Partnership reported 3,900 shares.

The stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) hit a new 52-week high and has $94.61 target or 3.00 % above today’s $91.85 share price. The 8 months bullish chart indicates low risk for the $6.02 billion company. The 1-year high was reported on May, 17 by Barchart.com. If the $94.61 price target is reached, the company will be worth $180.57 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock decreased 2.24% or $2.1 during the last trading session, reaching $91.85. About 1.35 million shares traded or 1.05% up from the average. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has risen 149.90% since May 17, 2017 and is uptrending. It has outperformed by 138.35% the S&P500.

Analysts await Sarepta Therapeutics, Inc. (NASDAQ:SRPT) to report earnings on July, 18. They expect $-0.57 earnings per share, up 50.43 % or $0.58 from last year’s $-1.15 per share. After $-0.44 actual earnings per share reported by Sarepta Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 29.55 % negative EPS growth.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Ratings Coverage

Among 14 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 12 have Buy rating, 0 Sell and 2 Hold. Therefore 86% are positive. Sarepta Therapeutics had 26 analyst reports since December 1, 2017 according to SRatingsIntel. On Wednesday, February 21 the stock rating was maintained by J.P. Morgan with “Buy”. The stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) earned “Buy” rating by SunTrust on Wednesday, March 7. The company was maintained on Friday, February 9 by Piper Jaffray. The firm has “Buy” rating by Leerink Swann given on Friday, January 19. SunTrust maintained it with “Buy” rating and $95.0 target in Thursday, March 15 report. Morgan Stanley maintained the stock with “Equal-Weight” rating in Friday, May 4 report. The stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has “Overweight” rating given on Wednesday, February 21 by JP Morgan. Leerink Swann maintained the shares of SRPT in report on Tuesday, March 13 with “Outperform” rating. The firm has “Overweight” rating given on Tuesday, March 6 by Morgan Stanley. The firm has “Outperform” rating given on Friday, May 4 by Credit Suisse.

More notable recent Sarepta Therapeutics, Inc. (NASDAQ:SRPT) news were published by: Seekingalpha.com which released: “The Market Has Spoken: Buy Sarepta” on May 07, 2018, also Streetinsider.com with their article: “UPDATE: Barclays Upgrades Sarepta Therapeutics (SRPT) to Overweight” published on May 11, 2018, Nasdaq.com published: “Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)” on April 30, 2018. More interesting news about Sarepta Therapeutics, Inc. (NASDAQ:SRPT) were released by: Investorplace.com and their article: “7 ‘Strong Buy’ Stocks Analysts Are Upgrading Now” published on May 14, 2018 as well as Nasdaq.com‘s news article titled: “Sarepta Therapeutics Announces Partnership with Myonexus Therapeutics for the Advancement of Multiple Gene …” with publication date: May 03, 2018.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA therapeutics for the treatment of rare neuromuscular diseases. The company has market cap of $6.02 billion. The firm offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy , which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It currently has negative earnings. It also develops SRP-4045 and SRP-4053, which are exon skipping clinical product candidates for the treatment of DMD.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.